Scarica l'app Stockscreener
125.12
1.25%
-1.59
Dopo l'orario di chiusura:
125.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$126.71
Aprire:
$126.575
Volume 24 ore:
5.86M
Relative Volume:
0.94
Capitalizzazione di mercato:
$217.57B
Reddito:
$43.84B
Utile/perdita netta:
$13.90B
Rapporto P/E:
15.69
EPS:
7.9725
Flusso di cassa netto:
$6.92B
1 W Prestazione:
+1.49%
1M Prestazione:
-3.75%
6M Prestazione:
-5.51%
1 anno Prestazione:
+11.78%
Intervallo 1D:
$124.93
$127.58
Intervallo di 1 settimana:
$122.91
$129.64
Portata 52W:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Confronta ABT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
125.12 | 220.33B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.11 | 140.06B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
353.11 | 134.83B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.48 | 126.02B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.80 | 49.23B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Abbott (ABT): Assessing Valuation After New Regulatory Wins for Its Pediatric Heart Device Innovation - Yahoo Finance
What Abbott Laboratories (ABT)'s New Pediatric Heart Device Clearances Mean For Shareholders - Yahoo Finance
Abbott's Amplatzer Piccolo(TM) Delivery System Receives FDA Clearance - marketscreener.com
Abbott Laboratories Receives FDA Clearance for Amplatzer Piccolo Delivery System - marketscreener.com
Can Abbott Laboratories (ABT) Deliver Resilient Returns in the Long Term? - Insider Monkey
Abbott wins FDA clearance, CE mark for Amplatzer Piccolo delivery system - MassDevice
New device helps doctors close heart holes in the tiniest preemies - Stock Titan
Peak Financial Advisors LLC Takes Position in Abbott Laboratories $ABT - MarketBeat
2 Dividend Stocks to Buy for 2026 and Beyond - Finviz
Abbott Laboratories $ABT Shares Purchased by Czech National Bank - MarketBeat
Chesley Taft & Associates LLC Sells 9,502 Shares of Abbott Laboratories $ABT - MarketBeat
Is Abbott Laboratories stock a smart buy before Fed meetingTrend Reversal & Weekly High Return Stock Opportunities - Улправда
RBC Capital Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $147 - 富途牛牛
Abbott Laboratories (NYSE:ABT) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Is Abbott Laboratories Still Attractively Priced After Recent Medical Device Momentum In 2025? - simplywall.st
Chris Blumas' Top Picks: Constellation Software, Brookfield Infrastructure & Abbott Labs - BNN Bloomberg
Transcatheter Heart Valve Replacement Market Size to Reach USD 19.98 Billion by 2033, Growing at a CAGR of 15.32% – SNS Insider - GlobeNewswire Inc.
Union Bancaire Privee UBP SA Sells 20,132 Shares of Abbott Laboratories $ABT - MarketBeat
Is Trending Stock Abbott Laboratories (ABT) a Buy Now? - Yahoo Finance
Thurston Springer Miller Herd & Titak Inc. Has $430,000 Stock Position in Abbott Laboratories $ABT - MarketBeat
Nilsine Partners LLC Cuts Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Shareholders Will Want The ROCE Trajectory To Continue - Yahoo Finance UK
Abbott Labs Slammed with Unpaid Wages Lawsuit - LawyersandSettlements.com
1 Safe-and-Steady Stock to Consider Right Now and 2 We Turn Down - FinancialContent
Abbott Seeks Federal Protection From Similac NEC Lawsuits - AboutLawsuits.com
TruWealth Advisors LLC Sells 109,352 Shares of Abbott Laboratories $ABT - MarketBeat
Insight Wealth Strategies LLC Invests $4.91 Million in Abbott Laboratories $ABT - MarketBeat
Capital Asset Advisory Services LLC Grows Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Home Diagnostics Market Is Going to Boom |• Abbott • Roche Diagnostics - openPR.com
Kidney Function Tests Market Is Going to Boom |• Abbott • Siemens - openPR.com
Reinventing the lab coat - Abbott
Why the Market Dipped But Abbott (ABT) Gained Today - Yahoo Finance
Gastrointestinal Diagnostics (GI) Market to Reach $5.8 Billion by 2030 - GlobeNewswire Inc.
Abbott Gains From Lingo CGM's Expansion on Android Platform - Nasdaq
Abbott Laboratories declares $0.063 dividend - MSN
Rep. Julie Johnson Sells Abbott Laboratories (NYSE:ABT) Stock - MarketBeat
Texas Permanent School Fund Corp Sells 65,976 Shares of Abbott Laboratories $ABT - MarketBeat
Stance Capital LLC Makes New $1.30 Million Investment in Abbott Laboratories $ABT - MarketBeat
Prostate Cancer Diagnostics Market Is Going to Boom |• Abbott • Siemens - openPR.com
Corient Private Wealth LLC Increases Holdings in Abbott Laboratories $ABT - MarketBeat
Caldwell Trust Co Takes Position in Abbott Laboratories $ABT - MarketBeat
17,830 Shares in Abbott Laboratories $ABT Bought by B. Riley Wealth Advisors Inc. - MarketBeat
Abbott Laboratories Strengthens Shareholder Returns Amid Strategic Acquisition - AD HOC NEWS
Abbott Laboratories (ABT) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025 - ts2.tech
MASTERINVEST Kapitalanlage GmbH Takes $8.54 Million Position in Abbott Laboratories $ABT - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Rhythm Pharmaceuticals (RYTM) - The Globe and Mail
Westwood Holdings Group Inc. Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Provident Investment Management Inc. - MarketBeat
Abbott Laboratories $ABT Shares Acquired by Public Sector Pension Investment Board - MarketBeat
Key facts: Abbott Laboratories appoints Nita Ahuja to Board; VP reports share gift - TradingView — Track All Markets
Bernstein Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $150 - 富途牛牛
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.73%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):